U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H23F3N4O2
Molecular Weight 468.4709
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MUBRITINIB

SMILES

FC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1

InChI

InChIKey=ZTFBIUXIQYRUNT-MDWZMJQESA-N
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

HIDE SMILES / InChI

Molecular Formula C25H23F3N4O2
Molecular Weight 468.4709
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.hoelzel-biotech.com/media/import/pdf_manual/Selleckchem//S2216-10__Manual.pdf https://www.ncbi.nlm.nih.gov/pubmed/16771730 http://adisinsight.springer.com/drugs/800019257

TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Mubritinib displays > 4000-fold selectivity over other tyrosine kinases, such as EGFR, FGFR, PDGFR, Jak1, Src and Blk. A Phase I study to investigate a safe dose of Mubritinib, once daily (QD), in patients with tumors known to express HER2 (Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm) has been completed, but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
2013 Apr 15
Patents

Sample Use Guides

Starting dose of TAK-165 10 mg, tablets, once daily with dose escalation to tolerability for 56 days.
Route of Administration: Oral
To evaluate TAK-165 sensitivity in vitro, after cells weretreated with TAK-165 at various concentrations continu-ously for 3 days. TAK-165 sensitivity depends on HER2 levels of each cellline. Especially, BT474 cells which over-express HER2strongly was highly sensitive (IC50 0.005 µmol/L) and PC-3 cells which express HER2 very weakly was less sensitive(IC50 4.62 µmol/L). But, HT1376 and ACHN cells thatover-expressed EGFR showed high IC50 (IC50 > 25 µmol/L).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:24:41 GMT 2023
Edited
by admin
on Fri Dec 15 16:24:41 GMT 2023
Record UNII
V734AZP9BR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MUBRITINIB
INN   USAN  
INN   USAN  
Official Name English
mubritinib [INN]
Common Name English
1-[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
Systematic Name English
1H-1,2,3-TRIAZOLE, 1-(4-(4-((2-((1E)-2-(4-(TRIFLUOROMETHYL)PHENYL)ETHENYL)-4-OXAZOLYL)METHOXY)PHENYL)BUTYL)-
Systematic Name English
MUBRITINIB [USAN]
Common Name English
TAK-165
Code English
Classification Tree Code System Code
NCI_THESAURUS C2167
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
Code System Code Type Description
FDA UNII
V734AZP9BR
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
INN
8446
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
PUBCHEM
6444692
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL1614707
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
NCI_THESAURUS
C66212
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
WIKIPEDIA
Mubritinib
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID501026014
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
DRUG BANK
DB12682
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
USAN
PP-49
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
EVMPD
SUB193705
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
CAS
366017-09-6
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
SMS_ID
100000178103
Created by admin on Fri Dec 15 16:24:41 GMT 2023 , Edited by admin on Fri Dec 15 16:24:41 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY